They treated CT26 tumor-bearing mice with an anti–Tim-3 antibody, anti-PD-L1 antibody, anti–Tim-3 plus anti–PD-L1 antibodies, or control immunoglobulins (59). This evidence concerns the gene HAVCR2 and neoplasm.